[1] 柴伟, 彭程. 血清生化指标对非酒精性脂肪性肝病的肝损伤评估价值. 肝脏, 2018, 23:71-73.
[2] Safiri S, Khazaei S, Mansori K, et al. Comments on increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 2017, 65:1358-1359.
[3] 张大鹍, 陈敏, 刘阳,等. ARFI与APRI指数对非酒精性脂肪性肝病肝纤维化的诊断价值. 中国临床医学影像杂志, 2013, 24:178-181.
[4] Klair J S, Yang J D, Abdelmalek M F, et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.. Hepatology, 2016, 64:85-91.
[5] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊断标准(一). 新医学, 2005, 7:364.
[6] 莫雪, 王崇, Klair JS. 雌激素的长期缺乏会增加非酒精性脂肪性肝病的绝经期妇女患肝纤维化的风险. 临床肝胆病杂志, 2016,32:1174.
[7] 吴瑞芝, 史惠蓉. 绝经妇女非酒精性脂肪肝病及绝经激素治疗的研究进展. 中国计划生育和妇产科, 2018,10:20-22. |
